GlassScriptPhysician profile
Kaushik Sen
NPI 1730110669
$25,042.95
in general payments reported to CMS, 2019-2025
68 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,912 · 2020: $1,828 · 2021: $3,148 · 2022: $3,228 · 2023: $3,381 · 2024: $3,161 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,341 · Education: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,340.64 |
| Education | $586.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $5,574.21 | 2019-2025 | Jakafi, Monjuvi |
| Genentech USA, INC. | $2,488.89 | 2019-2024 | Tecentriq, Rozlytrek, Alecensa |
| Novartis Pharmaceuticals Corporation | $1,687.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,310.06 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $1,165.39 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Pfizer INC. | $930.39 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $904.78 | 2019-2025 | Opdivo, Eliquis |
| Astrazeneca Pharmaceuticals LP | $883.56 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| Daiichi Sankyo INC. | $750.81 | 2019-2025 | Enhertu, Injectafer |
| Amgen INC. | $605.80 | 2019-2024 | Kyprolis, Lumakras, Blincyto |
| Celgene Corporation | $569.37 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $561.63 | 2019-2025 | |
| Eisai INC. | $469.84 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $407.92 | 2019-2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $403.04 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $379.49 | 2019-2024 | |
| Seagen INC. | $343.46 | 2019-2025 | Tukysa, Adcetris |
| Regeneron Healthcare Solutions, INC. | $303.11 | 2021-2025 | Libtayo |
| Lilly USA, LLC | $280.83 | 2019-2024 | Jaypirca, Retevmo, Verzenio |
| Gilead Sciences, INC. | $273.08 | 2019-2025 | Trodelvy |
| Sobi, INC | $270.40 | 2022-2025 | |
| Glaxosmithkline, LLC. | $257.55 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $246.39 | 2021-2025 | |
| Beigene USA, INC. | $233.22 | 2020-2025 | Brukinsa |
| Astellas Pharma US INC | $213.44 | 2019-2025 | Padcev, Xtandi, Xospata |
| Rigel Pharmaceuticals, INC. | $194.72 | 2019-2024 | Rezlidhia, Tavalisse |
| Karyopharm Therapeutics INC. | $191.83 | 2020-2025 | Xpovio |
| Puma Biotechnology, INC. | $172.95 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $169.94 | 2022-2023 | |
| Shield Therapeutics INC | $157.40 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.93 | 2019-2023 | Gilotrif |
| Exelixis INC. | $138.54 | 2019-2024 | Cabometyx |
| Array Biopharma INC | $131.95 | 2021-2024 | Braftovi, Mektovi, Lorbrena |
| Kite Pharma, INC. | $131.13 | 2020-2023 | Yescarta |
| Alexion Pharmaceuticals, INC. | $127.64 | 2019-2024 | Ultomiris |
| Adc Therapeutics America, INC. | $123.92 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $123.62 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $120.55 | 2021-2024 | Zepzelca |
| Emd Serono, INC. | $112.94 | 2020-2025 | Bavencio |
| Dova Pharmaceuticals | $112.80 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $106.41 | 2019-2024 | Xarelto |
| Servier Pharmaceuticals LLC | $96.56 | 2021-2025 | |
| Pharmacosmos Therapeutics INC. | $91.44 | 2024 | Cosela, Monoferric |
| Taiho Oncology, INC. | $87.86 | 2019-2024 | |
| Tersera Therapeutics LLC | $87.14 | 2020-2025 | Xermelo |
| Morphosys, US INC. | $84.89 | 2021-2023 | Monjuvi |
| Agios Pharmaceuticals, INC. | $81.51 | 2019-2024 | Pyrukynd |
| Recordati_rare_diseases_inc. | $68.40 | 2023-2024 | Sylvant, Panhematin |
| Mylan Institutional INC. | $66.41 | 2019-2020 | |
| Pharmaessentia USA Corporation | $58.44 | 2022-2024 | Besremi |
| Genmab U.S., INC. | $55.20 | 2024 | Tivdak |
| Clovis Oncology, INC. | $52.00 | 2020-2021 | |
| Adaptive Biotechnologies Corporation | $51.20 | 2023-2024 | Clonoseq |
| Deciphera Pharmaceuticals INC. | $48.27 | 2021-2022 | |
| Acceleron Pharma, INC. | $42.09 | 2020-2021 | |
| Tg Therapeutics, INC. | $41.62 | 2021-2022 | |
| Menarini Silicon Biosystems, INC. | $37.83 | 2025 | |
| Kyowa Kirin, INC. | $37.78 | 2019-2024 | Poteligeo |
| Heron Therapeutics, INC. | $23.75 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $23.15 | 2019 | |
| Tesaro, INC. | $21.31 | 2019 | |
| Spectrum Pharmaceuticals INC. | $18.84 | 2023 | Rolvedon |
| Fortovia Therapeutics, INC. | $17.82 | 2019 | |
| Immunomedics, INC. | $15.64 | 2020 | |
| Mirati Therapeutics, INC. | $15.60 | 2023 | Krazati |
| Verastem, INC. | $14.45 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.06 | 2022 | |
| Global Blood Therapeutics, INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaushik Sen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.